Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two
centres on patients with advanced cancer expressing EGFR. Primary objective is the
determination of the maximum tolerated dose (MTD) and recommended dose (RD) of the
combination of intravenous Cetuximab and oral Gefitinib.